Discontinued — last reported Q3 '12
Eli Lilly Total Non-Current Liabilities decreased by 0.5% to $50.71B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 40.6%, from $36.07B to $50.71B. Over 5 years (FY 2020 to FY 2025), Total Non-Current Liabilities shows an upward trend with a 12.4% CAGR.
A steady or declining trend relative to equity suggests improving long-term solvency, while rapid increases may signal aggressive expansion or recapitalization.
Total noncurrent liabilities represent the sum of all obligations not expected to be settled within the next year. This...
Analysts use this to calculate the debt-to-equity ratio, comparing the long-term risk profile against other mega-cap technology firms.
total_noncurrent_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $26.05B | $26.55B | $24.60B | $24.07B | $22.78B | $21.64B | $21.58B | $25.86B | $24.75B | $24.61B | $25.85B | $32.45B | $31.12B | $36.61B | $36.07B | $43.47B | $43.55B | $50.94B | $50.71B |
| QoQ Change | — | +1.9% | -7.4% | -2.1% | -5.3% | -5.0% | -0.3% | +19.8% | -4.3% | -0.6% | +5.0% | +25.5% | -4.1% | +17.7% | -1.5% | +20.5% | +0.2% | +17.0% | -0.5% |
| YoY Change | — | — | — | — | -12.5% | -18.5% | -12.3% | +7.4% | +8.6% | +13.7% | +19.8% | +25.5% | +25.7% | +48.8% | +39.5% | +34.0% | +40.0% | +39.1% | +40.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.